Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDFT1 | P37268 | 1/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 6/20 | 0.48 |
| ▸ | NPC1 | O15118 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.46 |
| ▸ | STAT1 | P42224 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | NPY2R | P49146 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL248915 | 0.94 | RAB9A (0.50) | FDFT1TDP1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL3033970 | 0.92 | FDFT1 (0.55) | FDFT1TDP1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL15952966 | 0.89 | CA12 (0.50) | FDFT1TDP1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL31386285 | 0.85 | PDE4B (0.53) | FDFT1PDE4BTDP1MAPTSMN1; SMN2 | |
| SCHEMBL26093038 | 0.83 | FDFT1 (0.46) | FDFT1TDP1MAPTRAB9ANPC1 | |
| SCHEMBL26092030 | 0.83 | FDFT1 (0.46) | FDFT1TDP1MAPTRAB9ANPC1 | |
| SCHEMBL17389542 | 0.81 | FDFT1 (0.58) | FDFT1TDP1RAB9ACYP19A1 | |
| SCHEMBL4003420 | 0.80 | CA12 (0.59) | FDFT1TDP1MAPTRAB9ANPC1 | |
| SCHEMBL1789154 | 0.79 | ALDH1A1 (0.63) | FDFT1MAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL8040438 | 0.79 | NAMPT (0.54) | FDFT1MAPTSMN1; SMN2ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2401265-B1 | DERIVATIVES OF 1-PYRI(MID)IN-2-YL-PYRAZOLE-4-CARBOXYLIC ACID WHICH ARE USEFUL FOR THERAPY OR PROPHYLAXIS OF CARDIOVASCULAR DISEASES | MERCK SHARP & DOHME (US) | 2016-09-14 | — | — | EP | disclosed |
| US-8507512-B2 | Soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2013-08-13 | — | — | US | disclosed |
| US-20100216764-A1 | Soluble Guanylate Cyclase Activators | MERCK SHARP & DOHME LLC | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216764-A1 | Soluble Guanylate Cyclase Activators | GUCY1B1, GUCY1A1, GUCY1A2 | FDFT1 525/4885PDE4B 16/4885TDP1 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.